Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1039 | 1039 | 1081 | 1313 | 1315 | 1738 |
Fund Return | 3.93% | 3.93% | 8.13% | 9.51% | 5.63% | 5.68% |
Place in category | 204 | 204 | 287 | 68 | 102 | 115 |
% in Category | 29 | 29 | 44 | 16 | 22 | 35 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
HSBC American Index Fund Accumulati | 13.81B | 11.23 | 14.50 | 15.81 | ||
HSBC American Index Fund Income C | 13.81B | 11.22 | 14.49 | 15.80 | ||
HSBC American Index Fund Retail Acc | 13.81B | 7.05 | 14.75 | 15.32 | ||
HSBC American Index Fund Retail Inc | 13.81B | 7.05 | 15.24 | 15.46 | ||
HSFund Institutional Accumulation | 13.81B | 7.07 | 14.89 | 15.50 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Index Unit Trust Accumulation | 13.73B | 4.02 | 7.99 | 5.79 | ||
All Share Index Unit Trust Income | 13.73B | -0.70 | 7.89 | - | ||
VG UK Plus GBP Accumulation | 13.73B | -0.70 | 7.91 | - | ||
VG UK Institutional Plus GBP Income | 13.73B | -0.69 | 7.90 | - | ||
UK Equity Tracker Fund X Acc | 11.33B | 2.83 | 7.92 | 5.85 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Shell | GB00BP6MXD84 | 8.50 | 33.75 | +0.04% | |
AstraZeneca | GB0009895292 | 7.89 | 12,156.0 | -0.12% | |
HSBC | GB0005405286 | 5.94 | 705.00 | +1.08% | |
Unilever | GB00B10RZP78 | 4.90 | 48.81 | +0.64% | |
BP | GB0007980591 | 4.12 | 515.80 | +1.26% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | Strong Buy | Strong Buy | Strong Buy |
Summary | Strong Buy | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review